Blog - Litchlab

EN

CN

{$ImageUrl,alt}

Blog

Home>Blog

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine Delivery

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine DeliveryLiposomes, as crucial carriers for vaccine delivery, possess unique structural and functional characteristics that enable them to meet the complex needs of various vaccines. Fr...

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma In May 2024, the U.S. Food and Drug Administration (FDA) announced the approval of irinotecan lipos...

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development Driven by the COVID-19 pandemic, mRNA vaccines and lipid nanoparticle (LNP) delivery systems have become key technologies i...

Litchlab Expands Its Small Molecule API CDMO Services to Accelerate Global Drug Development

[April 14, 2025] — Litchlab, a specialized CDMO dedicated to advanced drug delivery technologies and pharmaceutical raw materials, proudly announces the expansion of its Small Molecule Active Pharmaceutical Ingredient (API) R&D and GMP Manufacturing Platfo...

Litchlab Expands Comprehensive API Services to Accelerate Drug Development for Global Pharma Partners

[April 14, 2025] — Litchlab, a specialized Contract Development and Manufacturing Organization (CDMO), proudly announces the expansion of its Active Pharmaceutical Ingredient (API) services, offering an integrated solution for pharmaceutical innovators seeking...

Litchlab — Your Reliable CDMO Partner for API Development and GMP Manufacturing

As an integrated CDMO with proven expertise in drug delivery systems, Litchlab also provides end-to-end services for Active Pharmaceutical Ingredient (API) development and manufacturing, helping global pharmaceutical partners bridge the gap from early-stage di...

更换36.jpg

Litchlab | Your CDMO Partner for Microsphere & Nanoparticle Drug Delivery Systems

Litchlab is a specialized CDMO dedicated to the development, optimization, and GMP-compliant manufacturing of advanced microsphere and nanoparticle-based drug delivery systems. Our integrated services help pharmaceutical partners overcome formulation challenge...

Litchlab | Your Trusted Partner for Liposome-Based Drug Delivery Solutions

Litchlab is a specialized CDMO dedicated to the research, development, and production of liposome-based drug delivery systems. We offer comprehensive services that cover the entire drug development cycle — from early-stage formulation design to clinical batch ...

Litchlab: Empowering the Next Wave of Precision Therapeutics with Full-Spectrum ADC & RDC CDMO Solutions

As precision medicine reshapes the treatment paradigm for oncology and beyond, Antibody-Drug Conjugates (ADCs) and Radiopharmaceutical Drug Conjugates (RDCs) have emerged as powerful therapeutic modalities that unite specific targeting with potent cytotoxic or...

上一页 1 2 3 4 5 下一页